The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

Deletion of CDKN2A (p16) or amplification of CCND1 (cyclin D1) occurs commonly in head and neck squamous cell carcinoma (HNSCC) and induces sustained cyclin-dependent kinase (CDK) 4/6 activation. Here, we report the antiproliferative activity of LY2835219, a selective CDK4/6 inhibitor through inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ku, Bo Mi, Yi, Seong Yoon, Koh, Jiae, Bae, Yeon-Hee, Sun, Jong-Mu, Lee, Se-hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924753/
https://www.ncbi.nlm.nih.gov/pubmed/26909611
http://dx.doi.org/10.18632/oncotarget.7543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924753/
https://www.ncbi.nlm.nih.gov/pubmed/26909611
http://dx.doi.org/10.18632/oncotarget.7543

Ejemplares similares